As a whole, ADAM12 is now considered as a negative prognosis marker for human bladder [10,17] and breast cancers [18,19] and is suggested to be an important player in tumor-stromal crosstalk that supports tumor progression [20]. Here, ADAM12 is linked to breast carcinoma.